--News Direct--
BenevolentAI CEO Dr Joerg Moeller tells Proactive's Stephen Gunnion how the company is positioning itself as a pioneer in AI-augmented drug discovery, aiming to enhance the success rates of drug development by identifying optimal targets early in the process.
The company operates on three strategic pillars: advancing its proprietary pipeline of molecules for high medical need indications with limited treatment options, offering comprehensive drug discovery services through collaborations with notable industry partners such as AstraZeneca and Merck KGaA, and providing a Software as a Service (SaaS) platform for knowledge exploration.
This multi-faceted approach not only drives BenevolentAI's scientific endeavours but also underpins its business model, which generates revenue through pipeline progression, collaboration milestones, and the innovative SaaS offering. A key example of the platform's validation is the repurposing of baricitinib, an Eli Lilly drug, for COVID-19 treatment based on BenevolentAI's insights.
Dr Moeller's belief in AI's transformative potential in R&D is reinforced by the company's capabilities and the dedication of its team.
Near-term milestones include anticipated results from a Phase 1a study of their lead program in ulcerative colitis, with strategic goals focusing on pipeline advancement, forging more partnerships, and exploring the viability of their SaaS model for sustainable growth.
Contact Details
Proactive North America
Proactive North America
+1 604-688-8158
NA-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/benevolentai-ceo-dr-joerg-moeller-discusses-ais-impact-on-drug-discovery-635260576
